Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70565 | 0.82 | AKR1B1 (0.71) | AKR1B1CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL15042258 | 0.81 | SLC7A5 (0.55) | FFAR1FFAR4KDM4EMAPTHPGD | |
| SCHEMBL11257717 | 0.81 | AKR1B1 (0.58) | AKR1B1CYP1A2CYP2C19PTGDR2KDM4E | |
| SCHEMBL19032369 | 0.81 | CA2 (0.54) | AKR1B1FFAR1KDM4EMAPTHPGD | |
| Hydrochloric Acid SCHEMBL8922940 | 0.80 | AKR1B1 (0.68) | AKR1B1CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL3294256 | 0.79 | ENPP2 (0.42) | FFAR1FFAR4PTGDR2TSHRRCE1 | |
| SCHEMBL35452 | 0.79 | FOLH1 (0.58) | NFKB1HIF1A | |
| SCHEMBL31401245 | 0.79 | FOLH1 (0.58) | NFKB1HIF1A | |
| SCHEMBL335277 | 0.79 | ALDH1A1 (0.54) | AKR1B1CYP1A2CYP2C19PTGDR2HSD17B10 | |
| SCHEMBL19332366 | 0.78 | TSHR (0.49) | AKR1B1CYP1A2CYP2C19PTGDR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | SYNHALE THERAPEUTICS INC. | 2017-12-28 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-8865718-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 337/4885CYP1A2 1673/4885CYP2C19 1281/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | AKR1B1 520/4885CYP1A2 1613/4885CYP2C19 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.